Manuscripts and/or articles published as author or a contributor:

2005

Effectiveness of Azelastine Nasal Spray Compared with Oral Cetirizine in Patients with Seasonal Allergic Rhinitis. Clinical Therapeutics Vol. 27, no. 5, May 2005. Authors: Jonathon Corren, MD; William Storms, MD; Jonathan Berstein, MD; William Berger, MD; Anjuli Nayak, MD; and Harry Sacks, MD; for the Azelastine Cetirizine Trial No. 1 (ACT 1) Study Group.


Montelukast for Treating Fall Allergic Rhinitis: Effect of Pollen Exposure in Three Studies. Annals of Allergy, Asthma and Immunology 2004 Mar;92(3):367-73. Authors: Paul Chervinsky, MD; George Philip, MD; Marie-Pierre Malice, PhD; Jose Bardelas, MD; Anjuli Nayak, MD; Jean-Louis Marchal, PhD; Janet van Adelsberg, MD; Jean Bousquet, MD; Carol A. Tozzi, PhD; Theodore F. Reiss, MD.


2003

A Randomized Trial of Etanercept as monotherapy for psoriasis. Arch Dermatol 2003 Dec;139(12):1627-32. Authors: Alice B. Gottlieb, Clinical Research Center, New Brunswick, NJ; Robert T. Matheson, Oregon Medical Research Center; Nicholas Lowe, Clinical Research Specialists; Gerald G. Krueger, University of Utah Department of Dermatology; Sewon Kang, University of Michigan Department of Dermatology; Bernard S. Gofe, Minor James Medical; Anthony A. Gaspari, University of Rochester Medical Center; Mark Ling, MedaPhase, Inc.; Gerald D. Weinstein, University of California, Irvine, CA; Anjuli Nayak, Innovative Clinical Solutions, Inc.; Kenneth B. Gordon, Northwestern University Medical Center, Anyang Feng, Immunex Corp.; M.E. Lebsack, Immunex Corp.

The Asthma and Allergic Rhinitis Link. Allergy and Asthma Proceedings 2003 Nov-Dec;24(6):395-402. Author: Anjuli S. Nayak, M.D.

Tolerability of Re-Treatment with Omalizumab, a Recombinant Humanized Monoclonal Anti-IgE Antibody, During a Second Ragweed Pollen Season in Patients with Seasonal Allergic Rhinitis. Allergy and Asthma Proceedings 2003 Sep-Oct;24(5):323-29. Authors: Anjuli Nayak, MD, Thomas Casale, MD, S David Miller, MD, John Condeni, MD, Margaret McAlary, MS, Angel Fowler-Taylor, RPh, Giovanni Della Cioppa, MD, Niroo Gupta, MD, PhD.


2002

Efficacy and Safety of Beclomethasone Dicronionate Extrafine Aerosol in Childhood Asthma* A 12-Week, Randomized,

A Common Pathway: Asthma and Allergic Rhinitis. Allergy and Asthma Proceedings 2002 Nov-Dec;23(6):359-65. Authors: Anjuli Seth Nayak, MD, University of Illinois College of Medicine, Peoria, IL.

Omalizumab Improves Asthma-related Quality of Life in Children with Allergic Asthma. Pediatrics 2002 Nov;110(5). Authors: Robert F. Lemanske, Jr., MD, University of Wisconsin, Madison, WI; Anjuli Nayak, MD, University of Illinois, Peoria, IL; Margaret McAlary, MS, Novartis Pharmaceuticals Corp, East Hanover, NJ; Francois Everhard, PhD, Novartis Pharma AG, Basel, Switzerland; Angel Fowler-Taylor, RPh, Novartis Pharmaceuticals Corp, East Hanover, NJ; Niroo Gupta, MD, Novartis Pharmaceuticals Corp, East Hanover, NJ.

Update on Pediatric Asthma: Current Issues and Management Strategies. A supplement to Pediatric News - Proceedings of a Clinical Roundtable. James P. Kemp, MD; Jay A. Markson, MD; Anjuli S. Nayak, MD; Gary Rachelefsky, MD; Stanley J. Szeffler, MD.

Effective dose range of Mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Annals of Allergy, Asthma and Immunology Vol. 89, September 2002. Anjuli S. Nayak, MD, University of Illinois, College of Medicine, Peoria, IL; Guy A. Settipane, MD, Asthma, Nasal Disease & Allergy Research of New England, Providence, RI; Andrew Pedino, MD, Princeton Allergy & Asthma Research, Princeton, NJ; B. Lauren Charous, MD, Milwaukee Medical Clinic, Advanced Healthcare, SC, Milwaukee, WI; Eli O. Meltzer, MD, Allergy & Asthma Medical Group & Research Center, APC, San Diego, CA; William W. Busse, MD, University of Wisconsin Clinical Sciences Center, Madison, WI; S. James Zinreich, MD; Johns Hopkins Medical Institutions, Baltimore, MD; Richard R. Lorber, MD, Schering-Plough Research Institute, Kenilworth, NJ; Ger Rikken, MD, Schering-Plough Research Institute, Kenilworth; Melvyn R. Danzig, PhD, Schering-Plough Research Institute, Kenilworth; and the Nasonex Sinusitis Group.

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Annals of Allergy, Asthma and Immunology Vol. 88, June 2002. Authors: Anjuli S. Nayak, MD, University of Illinois, College of Medicine, Peoria, IL; George Philip, MD., Merck & Co., Rahway, NJ; Susan Lu, PharmD, Merck & Co., Rahway, NJ; Marie-Pierre Malice, PhD, Merck & Co., Rahway, NJ; Theodore F. Reiss, MD, Merck & Co., Rahway, NJ; and Montelukast Fall Rhinitis Investigator Group.

2001

Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis. JAMA Vol. 286 no. 23, December 19, 2001. Authors: Thomas B. Casale, MD, Department of Medicine, Creighton University, Omaha, NE; John Condemi, MD, University of Rochester, Rochester, NY; Craig LaForce, MD, North Carolina Clinical Research Institute, Raleigh, NC; Anjuli Nayak, MD, University of Illinois at Chicago, Chicago, IL; Michael Rowe, MD, Michigan Respiratory Health and Research Institute, Novi, MI; Marc Watrous, PhD, Genentech, Inc., San Francisco, CA; Margaret McAlary, MS, Novartis Pharmaceuticals Corp., East Hanover, NJ; Angel Fowler-Taylor, RPh, Novartis Pharmaceuticals Corp., East Hanover, NJ; Amy Racine, PhD, Novartis Pharma AG, Basle, Switzerland; Niroo Gupta, MD, PhD, Novartis Pharmaceuticals Corp., East Hanover, NJ; Robert Frick, MD, Genentech, Inc., San Francisco, CA; Giovanni Della Cioppa, MD, Novartis Horsham Research Centre, Horsham, England.


Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab). Pediatrics Vol. 108 No. 2, August 2001. Authors: Henry Milgrom, MD, National Jewish Medical and Research Center, Denver, CO; William Berger, MD, Southern California Research Center, Mission Viejo, CA; Anjuli Nayak, University of Illinois, Peoria, IL, Niroo Gupta, MD, Novartis Pharmaceuticals, East Hanover, NJ; Stephen Pollard, MD, Allergy & Asthma Research Institute, Louisville, KY; Margaret McAlary, Novartis Pharmaceuticals, East Hanover, NJ; Angel Fowler, RPh, Novartis Pharmaceuticals, East Hanover, NJ; Patricia Rohane, MD, Schering-Plough Corporation, Kenilworth, NJ.

Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. International Journal of Dermatology 2001, 40, 1-5. Johannes Ring, MD; Rudiger Hein, MD; Anke Gauger, MD; Edwin Bronsky, MD; Bruce Miller, MD; and the Desloratadine Study Group. (Cited as trial site)

Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56(11):1077 -80. Authors: A.S. Nayak, MD, School of Medicine, University of Illinois, Peoria, IL; E. Schenkel, MD, Valley Clinical Research Center, Easton, PA.

Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic Rhinitis, Assessment during the Spring and Fall Allergy Seasons. Clin Drug Invest 21 (1):25-32, 2001. Authors: Eli O. Meltzer, Allergy and Asthma Medical Group and Research Center, San Diego, California, USA; Bruce M. Prenner, Allergy Associates Medical Group, San Diego, California, USA; Anjuli Nayak, Peoria School of Medicine, University of Illinois, Peoria, Illinois, USA; and the Desloratadine Study Group.


Once Daily Mometasone Furoate Dry Powder Inhaler in the Treatment of Patients with Persistent Asthma. Annals of Allergy, Asthma, & Immunology 84(4):417, April 2000. Anjuli S Nayak, MD, Asthma & Allergy Research Associates, SC, Normal, IL and Dept. of Pediatrics, Peoria School of Medicine, Peoria, IL; Charles Banod, MD, Allergy & Asthma Ctrs of Charleston, PA, Charleston, SC; Jonathan Corren, MD, Allergy Research Foundation, Inc., Los Angeles, CA; Barry K Feinstein, MD, Virginia Allergy & Pulmonary Associates, PC, Richmond, VA; Anthony Floreani, MD, University of Nebraska Medical Center, Omaha, NE; Bruce F Friedman, MD, Allergy, Asthma, Bronchitis and Immunology Associates, Fountian-Valley, CA; Alan Goldsobel, MD, Allergy & Asthma Associates, San Jose, CA; Gregory M Gottschlich, MD, Allergy & Asthma Affililates Research Center, Cincinnati, OH; Paul J Hannaway, MD, Allergy Affililates Inc., Salem MA; Kathy L Lamp, MD, Asthma & Allergy Associates, Rockville, MD; Robert J Lapidus, MD, Rocky Mountain Pulm. Medical Clinical Research, Wheat Ridge, CO; Michael Lawrence, MD, Center for Clinical Research, Taunton, MA; William Lumry, MD, Allergy & Asthma Research Associates, Dallas, TX; Zev Munk, MD, Breco Research, Houston, TX; David Pearlman, MD, Rockland Pulmonary Associates, PC, Denver, CO; Anthony T Scardella, MD, Asthma & Allergy Center at St. Peter's Medical Center, New Brunswick, NJ; Eric J Schenkel, MD, Valley Clinical Research Center, Easton, PA; Allen T Segal, MD, Allergy Associates Research, Dallas, TX; Nathan Segall, MD, Georgia Allergy & Respiratory Institute, Atlanta, GA; Bernard Silverman, MD, Long Island College Hospital, Brooklyn, NY; Lucy Shneyer, MS, Schering-Plough Research Institute, Kenilworth, NJ; Keith B Nolop, MD, Schering-Plough Research Institute, Kenilworth, NJ; and Judy E Harrison, MD, Schering-Plough Research Institute, Kenilworth, NJ


The Effects of Triamcinolone Acetonide Aqueous Nasal Spray on Adrenocortical Function in Children with Allergic Rhinitis. The Journal of Allergy and Clinical Immunology 101(2 Pt 1): 157-162, February 1998. Authors: Anjuli S. Nayak, MD, Asthma, Allergy, and Immunology (private practice), Normal, IL; Mark H. Ellis, MD, Department of Allergy/Immunology, Orange, CA; Gary N. Gross, MD, University of Texas Southwestern School of Medicine, Dallas, TX; Louis M. Mendelson, MD, Department of Allergy/Immunology, University of Connecticut School of Medicine, West Hartford, CT; Eric J. Schenkel, MD, Department of Allergy/Immunology, Hahnemann University, Easton, PA; Bobby Q. Lanier, MD, Harrison Department of Allergy/Immunology, Harris Hospital, Fort Worth, TX; Brandon Simpson, BS, Rhone-Poulenc Rorer, Collegeville; Mary Ellen Mullin, MT, Rhone-Poulenc Rorer, Collegeville; and Joseph A. Smith, MD, Astra USA, INC., Westborough

Abstract accepted for publication:

Phase 2b Study of the Novel Vaccine Amb a 1 Immunostimulatory DNA Conjugate AIC in Ragweed Allergic Adults. Accepted for publication at the European Respiratory Society Annual Congress, Munich-Germany, September 2-6, 2006. Authors: Anjuli S. Nayak, MD, William Busse, MD, Philip Korenblat, MD, Gary Gross, MD and Daniel Levitt, MD, PhD.

Efficacy of Treatment with Once-Daily Evening Dosing of Mometasone Furoate Dry Powder Inhaler 200 mg in Asthma Stratified by Baseline Severity. Submitted for publication at the 2006 American College of CHEST Physicians Annual Meeting, Salt Lake City, Utah, October 21-26, 2006. Authors: Joe W. Ramsdell, MD, Anjuli S. Nayak, MD, George W. Bensch, MD

Abstract submitted for publication:

Frequency and Impact of Nighttime Asthma Symptoms in Adults and Children. Accepted for publication at The American College of Allergy, Asthma & Immunology Annual Meeting, Philadelphia, November 9-15, 2006. Authors: A. S. Nayak, MD and B. Q. Lanier, MD.

Phase 2b Study of the Novel Vaccine Amb a 1 Immunostimulatory DNA Conjugate AIC in Ragweed Allergic Adults. Accepted for publication at The American College of Allergy, Asthma & Immunology Annual Meeting. Philadelphia, November 9-15, 2006. Authors: Anjuli S. Nayak, MD, William Busse, MD, Philip Korenblat, MD, Gary Gross, MD and Daniel Levitt, MD, PhD.


Manuscripts accepted for publication:

Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison. Accepted for publication in Journal of the American Academy of Dermatology. Authors: Zoe Draelos, MD, Anjuli Nayak, MD, David Pariser, MD, Jerome L. Shupack, MD, Katie Chon, RPh, Beatrice Abrams, PhD, Carle F. Paul, MD.

Mometasone Furoate Improves Congestion in Patients with Moderate-to-Severe Seasonal Allergic Rhinitis. Accepted for publication in Annals of Pharmacotherapy. Authors: William E. Berger, MD, Anjuli S. Nayak, MD.

Efficacy and Safety of Desloratadine/Pseudoephedrine 2.5/120 mg BID Tablet Versus the Components in the Treatment of Patients with Seasonal Allergic Rhinitis. Accepted for publication in Allergy and Asthma Proceedings. Authors: Paul Chervinsky, Anjuli Nayak, Anthony Rooklin.

Manuscripts submitted for publication:

Montelukast in the Treatment of Allergic Rhinitis: An Evidence-Based Review. Submitted for publication in Drugs. Authors: Anjuli Nayak, MD and Ronald B. Landdon.

The Judicious Use of Antibiotics and the Utility of Intranasal Corticosteroids in Acute Rhinosinusitis. Submitted for publication in American Journal of Medicine. Authors: Catherine Butkus Small, MD, Claus Bachert, MD, Valerie J. Lund, MS, Augustine Moscatello, MD, Anjuli S. Nayak, MD, William E. Berger, MD, MBA.
The Judicious Use of Antibiotics and Intranasal Corticosteroids in Acute Rhinosinusitis. Submitted for publication in American Family Physician. Authors: Anjuli S. Nayak, M.D.

Acute Rhinosinusitis: New Management Approaches for Primary Care. Submitted for publication in Journal of Infectious Diseases. Authors: Anjuli S. Nayak, M.D.

Ciclesonide Improves Lung Function and is Well Tolerated in Patients with Severe, Persistent Asthma. Submitted for publication in American Journal of Respiratory and Critical Care Medicine. Authors: William Busse, Michael Kaliner, David Bernstein, Anjuli Nayak, Sudeep Kundu, Donald Banerji.

Inhaled Mometasone Furoate from an HFA-227 Metered Dose Inhaler Reduces Oral Prednisone Requirements and Improves Lung Function of Patients with Severe Persistent Asthma. Submitted for publication in Respiratory Medicine. Authors: Jill P. Karpel, MD, Anjuli Nayak, MD, William Lumry, MD, Timothy Craig, DO, Edward Kerwin, MD, James E. Fish, MD, Barry Lutsky, MD.

Immunopathology of Psoriasis. Submitted for publication in Clinical Immunology. Author: Anjuli Nayak, MD.

Psoriasis Treatment Modalities. Submitted for publication in Clinical Immunology. Author: Dr. Anjuli Seth Nayak, University of Illinois College of Medicine.

Safety and Efficacy of Intermittent Treatment with Etanercept in Patients with Psoriasis. Submitted for publication in Journal of the American Academy of Dermatology. Authors: Anjuli S. Nayak, MD; Kenneth B. Gordon, MD; Alice B. Gottlieb, MD, PhD; Craig L. Leonardi, MD; Boni E. Elewskim, MD; Andrea Wang, MA; Angelika Jahreis, MD, PhD; and Ralph Zitnik, MD.

National and International Abstracts Submitted as author or contributor:

National and International Abstracts Presented and Published as Author or Contributor:

2006

Novel Amb a 1 CpG Oligodeoxyribonucleotide Conjugate Ragweed Vaccine Administered to Children. Accepted for publication at the 62nd Annual American Academy of Allergy, Asthma & Immunology, Miami Beach, Florida, March 3-7, 2006. Authors: A.S. Nayak, I. Tripathy, D. Levitt.

Ciclesonide has no Effect on Growth in Prepubertal Children with Mild, Persistent Asthma, Irrespective of Age and Gender. Accepted for publication at the 62nd Annual American Academy of Allergy, Asthma & Immunology, Miami Beach, Florida, March 3-7, 2006. Authors: A. Nayak, O. Herrera, S. Kundu, M. Lloyd, D. Banerji.


2005

Phase I Study of AMB A 1 Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Children. Presented at The American College of Allergy, Asthma & Immunology, Anaheim, California, November 4-9, 2005. Authors: A S Nayak, I Tripathy and D. Levitt.

Mometasone Furoate Nasal Spray Once Daily is Effective in Severe Nasal Congestion Associated with Seasonal Allergic Rhinitis. Presented at The American College of Allergy, Asthma & Immunology, Anaheim, California, November 4-9, 2005. Authors: WE Berger, AS Nayak, H Staudinger, D Gates.


R411 Treatment Reduces Exacerbation and Attenuates FEV1 Fall Following Steroid Withdrawal in Moderate Asthma. Presented at the 2005 European Respiratory Society, Copenhagen, Denmark, September 17-21, 2005. Authors: Alexis D Rames, MD; William B Busse, MD; Louis Renzetti, PhD and Anjuli S. Nayak, MD.

Safety Profile of Fexofenadine in Children Aged 6 Months to 2 Years with Allergic Rhinitis. Presented at World Allergy Congress, Munich, Germany June 26-July1, 2005. Authors: Nayak, Anjuli, Peoria School of Medicine, University of...


Tolerability and Treatment Response at Starting Doses of Triamcinolone Acetonide AQ and Budesonide AQ in Patients with Seasonal Allergic Rhinitis. Presented at Western Society of Allergy, Asthma and Immunology (WSAAAI), Princeville, Hawaii, January 23-27, 2005. Authors: A Nayak, W Berger, Y Liao, J Garcia, G Georges and the Study 4007 Investigator Group; Normal, IL, Mission Viejo, CA, Bridgewater, NJ.

2004


Ciclesonide does not Suppress the Hypothalamic-Pituitary-Adrenal-Axis Function in Patients with Severe Persistent Asthma: Results of a Long-Term Study. Presented at The American College of Allergy, Asthma & Immunology, Boston, MA, November 12-17, 2004. Authors: Nayak A, Nathan R, Williams J, Kundu S, Lloyd M, Banerji D.

Effect of Desloratadine on Quality of Life and Functional Sleep Outcome in Patients with Symptomatic Seasonal Allergic Rhinitis. Published at EAACI, Amsterdam, 2004. Authors: L E Mansfield, A S Nayak, T E Weaver, N J Amar, M F Goldstein, P Chervinsky, A G Harris.


Efficacy and Safety of Efalizumab in Patients with Moderate to Severe Plaque Psoriasis: Pooled Results from Three Phase III Randomized, Placebo-Controlled Trials. Presented at the American Academy of Allergy, Asthma, and Immunology 2004 Annual Meeting, March 19-23, 2004, San Francisco, CA. Author: A Nayak, University of Illinois, Peoria, IL.

2003

Asthma: From Genes to Clinical Management – Clinical Symposium on Therapeutic Options in Asthma. Presented at the XVII World Asthma Congress, July 5-8, 2003, Saint-Petersburg, Russia.

The Efficacy and Safety of a T-Cell Modulator, Efalizumab (Raptiva [trade]), in Patients with Moderate to Severe Plaque Psoriasis: Results from Phase III Trials. Presented at the Federation of Clinical Immunology Society Third Annual Meeting, May 15-19th 2003, Paris, France.

ENBREL® (Etanercept) Monotherapy in Patients with Psoriasis: Clinical and Pathologic Improvements. Presented at the American Academy of Allergy Asthma & Immunology 60th Annual Meeting, March 7-12, 2003, Denver, CO. Authors: A. Nayak (Peoria, IL), R. Zitnik (Seattle, WA)

2002

Improvements in Pulmonary Function with Mometasone Furoate Dry Powder Inhaler in Patients with Persistent Asthma Previously Maintained on Inhaled Short-Acting B2-Adrenergic Agonists: Efficacy Analysis Based on Baseline FEV1. Presented at the American College of Allergy, Asthma & Immunology Annual Meeting, November 16 &17th 2002, San Antonio, Texas. Authors: A.S. Nayak, MD, Asthma and Allergy Research Associates, SC, Normal, IL, USA; J.P. Kemp, MD, Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA; J.J. Murray, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA; L. Schneyer, Schering-Plough Research Institute, Kenilworth, NJ, USA.

Efficacy of Beclomethasone Difropionate (BDP) Extrafine Aerosol Following Switch From Conventional BDP in Children with Asthma. Presented at the American Academy of Asthma, Allergy, and Immunology 58th Annual meeting, March
1-March 6, 2002, New York, NY. Authors: A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL, Stanley J. Szefler, National Jewish Medical Research Center, Denver, CO, Soren Pedersen, University of Odense & Kolding Hospital, Kolding Denmark.

Systemic Safety of New Beclomethasone Dipropionate Extrafine Aerosol in Childhood Asthma. Presented at the American Academy of Asthma, Allergy, and Immunology 58th Annual meeting, March 1-March 6, 2002, New York, NY. Authors: M.J. Welch, Allergy & Asthma Medical Group & Research Center, San Diego, CA; S. F. Weinstein, Allergy & Asthma Specialist Medical Group, Huntington Beach, CA; R. Lanier, Lanier Education and Research Network, Fort Worth, TX; A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL; P. Stampone, 3M Pharmaceuticals, St. Paul, MN.

New Beclomethasone Dipropionate Extrafine Aerosol Is Effective Pediatric Asthma Therapy. Presented at the American Academy of Asthma, Allergy, and Immunology 58th Annual meeting, March 1-March 6, 2002, New York, NY. Authors: S. F. Weinstein, Allergy & Asthma Specialist Medical Group, Huntington Beach, CA; M.J. Welch, Allergy & Asthma Medical Group & Research Center, San Diego, CA; Lanier Education and Research Network, Fort Worth, TX; A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL; Stanley J. Szefler, National Jewish Medical Research Center, Denver, CO; P. Stampone, 3M Pharmaceuticals, St. Paul, MN.

Long-Term Safety of Extrafine and Conventional Beclomethasone Dipropionate Aerosols in Pediatric Asthma. Presented at the American Academy of Asthma, Allergy, and Immunology 58th Annual meeting, March 1-March 6, 2002, New York, NY. Authors: Stanley J. Szefler, National Jewish Medical Research Center, Denver, CO; A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL; Soren Pedersen, University of Odense & Kolding Hospital, Kolding Denmark.

Efficacy of Beclomethasone Dipropionate (BDP) Extrafine Aerosol Following Switch from Conventional BDP in Children with Asthma. Presented at the American Academy of Asthma, Allergy, and Immunology 58th Annual meeting, March 1-March 6, 2002, New York, NY. Authors: D. Donnell, 3M Pharmaceuticals, Loughborough, UK; A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL; Soren Pedersen, University of Odense & Kolding Hospital, Kolding Denmark.

2001

New Beclomethasone Dipropionate Extrafine Aerosol is Effective in Children With Asthma. Presented at the American College of Allergy, Asthma & Immunology(ACAAI), November 16th-18th, 2001. Authors: A. Nayak, Normal, IL; R. Lanier, Fort Worth, TX; P. Stampone, St. Paul, MN.

Comparative long-term safety of extrafine and conventional formulations of beclomethasone dipropionate asthma. Presented at the American College of Allergy, Asthma & Immunology(ACAAI), November 16th-18th, 2001. Authors: S. Szefler, Denver, CO; D. Staab, Berlin, Germany; A. Nayak, Normal, IL; U. Wahn, Berlin, Germany; J. Warner, Southampton, UK; J. Vanden Burgt, St. Paul, MN.

Comparative pediatric efficacy of beclomethasone dipropionate (BDP) extrafine aerosol following switch from chlorofluorocarbon-BDP with long term follow-up. Presented at the American College of Allergy, Asthma & Immunology(ACAAI), November 16th-18th, 2001. Authors: S. Szefler, Denver, CO; D. Staab, Berlin, Germany; A. Nayak, Normal, IL; U. Wahn, Berlin, Germany; J. Warner, Southampton, UK; J. Vanden Burgt, St. Paul, MN.

Omalizumab (Xolair) Improves Rhinoconjunctivitis-Specific Quality of Life in Patients with Perennial Allergic Rhinitis. Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001. Authors: Busse W., Madison, WI; Nayak A., Normal, IL; Chervinsky P., North Darmouth, MA, Casale T., Omaha, NE; Tripathy I.,
Omalizumab (Xolair) Improves Perennial Allergic Rhinitis in Patients Who Were Previously Unresponsive to Treatment with Nasal Steroids or Immunotherapy. Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001. Authors: Busse W., Madison, WI; Nayak A., Normal, IL; Chervinsky P., North Dartmouth, MA, Casale T., Omaha, NE; Tripathy I., Rolla, MO; Bernstein J., Cincinnati, OH; Condemi J., Rochester, NY; Fowler Taylor A., East Hanover, NJ; Shen H., East Hanover, NJ; Hedgecock S., Horsham, UK; Fox H., Horsham, UK; Everhard F., Basel, Switzerland.

Long Term Use of Once-Daily Mometasone Furoate Is Effective and Well Tolerated in Patients with Mild to Moderate Persistent Asthma. Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001. Authors: A.S. Nayak, MD, Asthma & Allergy Research Associates, SC, Normal, IL, USA; K.L. Lampl, MD, Asthma & Allergy Associates, Rockville, MD, USA; N. Segall, MD, Georgia Allergy & Respiratory Institute, Atlanta, GA, USA; J. Harrison, MD, Schering-Plough Research Institute, Kenilworth, NJ, USA.

Asthma and Rhinitis Induced by Cockroach Allergen in an Urbanized Russian Community. Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001. Authors: Anjuli S Nayak, David Nayak, Sandra Knapp, Clinical Research Center, Normal, IL.

Treatment of Allergic Rhinitis with Montelukast Alone or in Combination with Loratadine in a Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001. Authors: K Lis, K Malmstrom, A Nayak, G Philip, M-P Malice, TF Reiss, and the Montelukast Fall Rhinitis Investigator Group.

Persistent Severe Cow’s Milk Protein Allergy Secondary to Skin Contact. Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001. Authors: See-Long Wong and Anjuli S. Nayak, Clinical Research Center, Normal, IL.

Improvement in Rhinoconjunctivitis Quality of Life Outcomes in the Treatment of Fall Allergic Rhinitis by Montelukast Alone or in Combination with Loratadine in a Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001. Authors: G Philip, K Malmstrom, Merck & Co; A Nayak, Clinical Studies Bloomington-Normal, Normal, IL; Marie-Pierre Malice, Merck & Co; Theodore F Reiss, Merck & Co; and the Montelukast Fall Rhinitis Investigator Group, Merck & Co.

Omalizumab (Xolair) is Effective and Well Tolerated in the Treatment of Children with Allergic Asthma. Presented at the World Asthma Meeting, Chicago, July 2001. Authors: Milgrom H, National Jewish Medical and Research Center, Denver, USA; Nayak A, ICSL, Normal, USA; Berger W, Southern California Research Center, Mission Viejo, USA; Pollard S, Asthma and Allergy Research Institute, Louisville, USA; Watrous M, Genentech, USA; Doyle J, Novartis, USA; McAlary M, Novartis, USA; Gupta N, Novartis, USA; Fowler Taylor A, Novartis, USA.


Omalizumab (Xolair) is Effective and Well Tolerated in the Treatment of Children with Allergic Asthma. Presented at the World Asthma Meeting, Chicago, July 2001. Authors: Milgrom H, National Jewish Medical and Research Center, Denver, USA; Nayak A, ICSL, Normal, USA; Berger W, Southern California Research Center, Mission Viejo, USA; Pollard S, Asthma and Allergy Research Institute, Louisville, USA; Bensch G, Allergy, Immunology and Asthma Medical Group, Stockton, USA; Hampel F, Central Texas Health Research, New Braunfels, USA; McAlary M, Novartis, USA; Fick R, Genentech, USA; Fowler Taylor A, Novartis, USA; Gupta N, Novartis, USA.

Effects of Age on Response to Treatment with Mometasone Furoate Among Patients with Mild to Moderate Persistent Asthma. Presented at the ATS 2001 San Francisco, the 97th International Conference, San Francisco, May 2001.


2000

The Effects of Once-Daily Cetirizine HCL on Symptoms and Health-Related Quality of Life (HRQL) in Patients with Seasonal Allergic Rhinitis (SAR): Results of A Second Randomized Double-Blind Placebo Controlled Trial. Presented at the American College of Allergy, Asthma, and Immunology, November 2000, Seattle. Annals of Allergy, Asthma and...
Clinical Immunology, 86(1):83, January 2001. Authors: MJ Noonan, MD, Portland, OR; G Raphael, MD, Bethesda, MD; AS Nayak, MD, Normal, IL; L Greos, MD, Wheat Ridge, CO; AO Olufade, PharmD, MS; D Chapman, MS; B Kramer, MD, New York, NY.

Long Term use of Corticosteroids in Children: Comparative Safety and Efficacy of an Extrafine Beclomethasone Dipropionate Aerosol and a Conventional PMDI. Presented at the International Congress of Allergy, Asthma, and Immunology, October 2000, Australia.


Desloratadine Relieves Nasal Congestion in Patients with Seasonal Allergic Rhinitis. Presented at the Congress of the European Academy of Allergology and Clinical Immunology, July 2000, Spain.

Desloratadine Relieves Nasal Congestion in Patients with Seasonal Allergic Rhinitis. Presented at the XIXth Congress of the European Academy of Allergology and Clinical Immunology, July 2000, Lisbon, Portugal.


Decongestant Effects of Desloratadine in Patients with Seasonal Allergic Rhinitis. Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 2000.


1999

Once-daily Mometasone Furate dry powder is highly effective therapy for patients with mild to moderate persistent asthma. Presented at the American College of Asthma, Allergy, and Immunology Meeting, November 1999, Chicago, IL. Authors: A.S. Nayak, K.L. Lampi, N. Segall, K.B. Nolop,, and the C96-136 Study Group.


HPA-Axis Function in Infants and Young Children with Persistent Asthma Treated for 52 Weeks with Budesonide Inhalation Suspension (BIS; Pulmicort Respules). Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 1999, Orlando, FL.


HPA-Axis Function in Infants and Young Children with Persistent Asthma Treated for 52 Weeks with Budesonide Inhalation Suspension (BIS; Pulmicort Respules). Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 1999, Orlando, FL.


1998

A Six-Month, Placebo-Controlled Comparison of the Safety and Efficacy of Salmeterol or Beclomethasone as Monotherapy for Persistent Asthma. Presented at the American College of Asthma, Allergy, and Immunology Meeting, November 1998, Philadelphia, PA.


Asthma Severity as a Determinant for Selecting Appropriate Doses of Fluticasone Propionate (FP) or Beclomethasone Dipropionate (BDP). Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, 1998, Washington, DC.


1997


Long Term Treatment of Asthma With Zafirlukast (ACCOLATE): Results of a 13-Week Multicenter Trial in Patients with Moderate Airflow Obstruction. Presented at the International Congress of Asthma, Allergy, and Clinical Immunology Meeting, 1997, Cancun, Mexico.


Salmeterol Improves Asthma-Specific Quality of Life in Patients with Moderate Persistent Asthma. Presented at the AAAAI/AAAI/CIS Meeting, February 1997, San Francisco, CA.


Intranasal Fluticasone Propionate (FP) is More Effective Than Loratadine (LOR) For Treatment of Seasonal Allergic Rhinitis. Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, 1996, New Orleans, LA.


Articles published with Dr. Nayak’s citations


Potter PC. Levocetirizine is Effective for Symptom Relief Including Nasal Congestion in Adolescents and Adult (PAR) Sensitized to House Dust Mites. ALLERGY 58 (9): 893-899, Sep. 2003.


Noonan M., Karpel J.P., Bensch G.W., et al. Comparison of once-daily to twice-daily treatment with mometasone furoate


Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients...


Switching from Conventional to Extrafine Aerosol Beclomethasone Dipropionate Therapy in Children: